entinostat has been researched along with Adenocarcinoma Of Kidney in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orillion, A | 1 |
| Hashimoto, A | 1 |
| Damayanti, N | 1 |
| Shen, L | 2 |
| Adelaiye-Ogala, R | 1 |
| Arisa, S | 1 |
| Chintala, S | 1 |
| Ordentlich, P | 1 |
| Kao, C | 1 |
| Elzey, B | 1 |
| Gabrilovich, D | 1 |
| Pili, R | 4 |
| Ciesielski, M | 1 |
| Ramakrishnan, S | 1 |
| Miles, KM | 1 |
| Ellis, L | 1 |
| Sotomayor, P | 1 |
| Shrikant, P | 1 |
| Fenstermaker, R | 1 |
| Wang, XF | 1 |
| Qian, DZ | 1 |
| Ren, M | 1 |
| Kato, Y | 2 |
| Wei, Y | 1 |
| Zhang, L | 1 |
| Fansler, Z | 1 |
| Clark, D | 1 |
| Nakanishi, O | 1 |
| Yoshimura, K | 1 |
| Shin, T | 1 |
| Verheul, H | 1 |
| Hammers, H | 1 |
| Sanni, TB | 1 |
| Salumbides, BC | 1 |
| Van Erp, K | 1 |
| Schulick, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for entinostat and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.
Topics: Animals; Benzamides; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Disease Models, Animal; | 2017 |
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Topics: Acetylation; Animals; Benzamides; Carcinoma, Renal Cell; Castration; CD8-Positive T-Lymphocytes; Dis | 2012 |
Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Carcinoma, R | 2005 |
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Renal Cell; Cell Proliferation; Drug Synergis | 2007 |